2013-03-07 06:52:20 - New Market Research Report Added In MarketResearchReports.Biz Database China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant human insulin and insulin analog accounted for 52.8%.
To Buy The Copy Of This Report Visit: www.marketresearchreports.biz/analysis-details/china-insulin-ind ..


Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart- Tonghua Dongbao Pharmaceutical -occupied merely 3.4% or so.

Denmark-based Novo Nordisk is not only the leader in global insulin industry, but also a

major supplier in Chinas insulin market with the recombinant human insulin market share of 76% and the insulin analog market share of 53% in 2011.
To Read The Complete Report with TOC Kindly Visit: www.marketresearchreports.biz/analysis/158786


America-based Eli Lilly and Company is the second embarking on Chinese insulin market, with the recombinant human insulin market share of 17% and the insulin analog market share of 8% in 2011. Moreover, Eli Lilly and Company is making constant efforts to extend business in the Chinese market. In May, 2012, Eli Lilly and Company China R&D center was formally opened in Shanghai, dedicated to the R&D of diabetes medicines; in June, the Suzhou-based insulin extension project with the investment exceeding USD40 million was also put into service.?

Jilin-based Tonghua Dongbao Pharmaceutical is Chinas largest recombinant human insulin producer, with the insulin API capacity of 3,000 kg and the insulin preparation capacity of 70 million bottles or 6% market share in Chinas recombinant human insulin market. In 2012, the companys recombinant human insulin injection phase

To Buy The Copy Of This Report Visit: www.marketresearchreports.biz/analysis-details/china-insulin-ind ..